KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.96

NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial.

T Macarulla, R Pazo Cid, M S Womack, A Cubillo Gracian, A Zervoudakis, H Hatoum, V Chung, A Patel, A S Paulson, S Pant, E M O'Reilly, R A Hubner, E Van Cutsem, T Bekaii-Saab, L Zhang, J Li, H Chen, F Maxwell, Z A Wainberg, D Melisi

ESMO Open 11(3) 106043

PMID41687160
PMCIDPMC12925108
DOI10.1016/j.esmoop.2025.106043
发表日期2026-02-13
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
摘要

摘要

BACKGROUND: The phase III NAPOLI 3 trial established liposomal irinotecan in combination with 5-fluorouracil/leucovorin plus oxaliplatin (NALIRIFOX) as a superior first-line (1L) treatment option compared with gemcitabine plus nab-paclitaxel (Gem + NabP) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC), without imposing an upper age limit on enrollment. The current analysis of the NAPOLI 3 data investigated the potential impact of older age on the efficacy and safety of NALIRIFOX. PATIENTS AND METHODS: Adults with previously untreated mPDAC were randomly assigned in a 1 : 1 ratio to receive NALIRIFOX or Gem + NabP. This post hoc analysis compared outcomes for patients aged ≥70 years versus <70 years. Endpoints included overall survival (OS), progression-free survival (PFS), and safety. No statistical comparison was carried out. RESULTS: Of the 770 patients in the NAPOLI 3 population, 553 were aged <70 years and 217 were aged ≥70 years. Median OS and median PFS with NALIRIFOX were 11.7 months and 7.4 months, respectively, in the <70 years subgroup (n = 275) and 10.0 months and 7.3 months, respectively, in the ≥70 years subgroup (n = 108). The benefit of NALIRIFOX versus Gem + NabP was preserved in the older versus younger subgroup. There was no evidence of increased treatment-related toxicity in the older (versus younger) subgroup. CONCLUSIONS: NALIRIFOX improved mPDAC survival versus Gem + NabP irrespective of patient age, with no signals for reduced tolerability in the older (versus younger) patients. The results provide reassurance that triplet therapy with NALIRIFOX is an efficacious and tolerable regimen in older treatment-naive patients with mPDAC who were fit enough for inclusion in NAPOLI 3, supporting consideration of its use as 1L therapy in this population.

KM 提取结果

2 个 Figure · 4 个 KM 面板

进入结果中心
KM Figure2 个面板

Figure 1

Figure 1 Kaplan–Meier estimates. OS in patients aged (A) <70 years and (B) ≥70 years. CI, confidence interval; Gem, gemcitabine; HR, hazard ratio; NabP, nab-paclitaxel; NALIRIFOX, liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin; OS, overall survival. a Unstratified Cox model.

A

OS

Figure 1 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

OS

Figure 1 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure2 个面板

Figure 2

Figure 2 Kaplan–Meier estimates. PFS in patients aged (A) <70 years and (B) ≥70 years. CI, confidence interval; Gem, gemcitabine; HR, hazard ratio; NabP, nab-paclitaxel; NALIRIFOX, liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin; PFS, progression-free survival. a Unstratified Cox model.

A

PFS

Figure 2 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

PFS

Figure 2 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

captionless-figureGraphical abstract
非 KM Figure